Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of ArTiMist™ in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient's parent or attendant relative has provided informed consent and the patient has assented (where relevant) to participation in the trial~2. The patient is a child that weighs between 5 and 15 kg (kilogram)~3. The patient has falciparum malaria as evidenced by~   1. Thick or thin blood smears of \> 500 P falciparum per mcl (microlitre)(patients with mixed infections may be included provided \>500 P Falciparum /mcl) and /or~  2. Positive RDT (rapid diagnostic test)for malaria~4. The patient has either~   1. severe or complicated malaria as determined by the Investigator based on the WHO criteria for severity, or~  2. the patient has uncomplicated malaria but is unable to tolerate oral medication as a result of gastrointestinal complications such as vomiting or diarrhoea.~Exclusion Criteria:~1. Attending relative or parent does not provide informed consent for participation, or the child if capable does not assent to participation in the trial.~2. Ability to tolerate oral therapy~3. Patient has received any treatment with an artemisinin or quinine in the last 24 hours~4. Patient has evidence of significant co-infections (this does not include mixed Plasmodium infections).~5. Patient is allergic or intolerant to artemisinins.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ArTiMist (artemether sublingual spray) (Type: EXPERIMENTAL): None
- Intravenous Quinine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).